DG
DGX.US Quest Diagnostics Incorporated
- Market cap
- USD 28.6B
- P/E
- 25.9x
- P/B
- 3.74x
- ROE
- 15.4%
- Dividend yield
- 1.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DGX.US undervalued?
Graham numberDGX.US trades 107.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quest Diagnostics Incorporated fundamental analysis
No fundamental analysis for Quest Diagnostics Incorporated yet.
Quest Diagnostics Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consum…
Full company profileQuest Diagnostics Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Quest Diagnostics Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.52B | 7.71B | 7.53B | 7.73B | 9.44B | 10.8B | 9.88B | 9.25B | 9.87B | 11.0B | 12.0B |
| Gross Profit | 2.90B | 2.99B | 2.61B | 2.69B | 3.63B | 4.21B | 3.43B | 3.05B | 3.24B | 3.52B | 4.01B |
| Operating Income | 1.28B | 1.17B | 1.10B | 1.23B | 1.97B | 2.38B | 1.43B | 1.26B | 1.35B | 1.60B | 1.78B |
| EBITDA | 1.48B | 1.45B | 1.40B | 1.59B | 2.41B | 3.16B | 1.82B | 1.26B | 1.89B | 2.19B | 2.34B |
| Net Income | 645M | 772M | 736M | 858M | 1.43B | 2.00B | 946M | 854M | 871M | 992M | 1.18B |
| EPS | 4.54 | 5.51 | 5.29 | 6.31 | 11 | 16 | 8.02 | 7.56 | 7.71 | 8.78 | 11 |
| Balance Sheet | |||||||||||
| Total Assets | 10.1B | 10.5B | 11.0B | 12.8B | 14.0B | 13.6B | 12.8B | 14.0B | 16.2B | 16.2B | 17.2B |
| Total Liabilities | 5.36B | 5.47B | 5.66B | 7.08B | 7.14B | 7.05B | 6.83B | 7.60B | 9.26B | 8.94B | 9.19B |
| Shareholders' Equity | 4.63B | 4.92B | 5.22B | 5.64B | 6.76B | 6.44B | 5.89B | 6.31B | 6.78B | 7.17B | 7.63B |
| Cash & Short-term Investments | 359M | 137M | 135M | 1.19B | 1.16B | 872M | 315M | 686M | 549M | 420M | 797M |
| Total Debt | 3.73B | 3.86B | 3.99B | 5.42B | 4.81B | 4.77B | 4.71B | 5.50B | 7.09B | 6.92B | 6.29B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.07B | 1.18B | 1.20B | 1.24B | 2.01B | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B | 1.98B |
| Capital Expenditure | 293M | 252M | 383M | 400M | 418M | 403M | 404M | 408M | 425M | 527M | 557M |
| Free Cash Flow | 776M | 923M | 817M | 843M | 1.59B | 1.83B | 1.31B | 864M | 909M | 1.36B | 1.42B |
| Ratios | |||||||||||
| ROE | 13.9% | 15.7% | 14.1% | 15.2% | 21.2% | 31.0% | 16.1% | 13.5% | 12.9% | 13.8% | 15.4% |
| ROA | 6.4% | 7.4% | 6.7% | 6.7% | 10.2% | 14.7% | 7.4% | 6.1% | 5.4% | 6.1% | 6.8% |
| Net Profit Margin | 8.6% | 10.0% | 9.8% | 11.1% | 15.2% | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% | 9.8% |
| Debt to Equity | 0.81x | 0.78x | 0.77x | 0.96x | 0.71x | 0.74x | 0.80x | 0.87x | 1.05x | 0.96x | 0.82x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Quest Diagnostics Incorporated dividends
- Dividend yield
- 1.24%
- Forward dividend
- 3.44 USD
- Payout ratio
- 35.6%
- Ex-dividend date
- Jan 12, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 353M | 3.12 | 35.6% |
| 2024 | USD 331M | 2.93 | 38.0% |
| 2023 | USD 314M | 2.78 | 36.8% |
| 2022 | USD 305M | 2.58 | 32.2% |
| 2021 | USD 309M | 2.41 | 15.5% |
| 2020 | USD 297M | 2.18 | 20.8% |
| 2019 | USD 286M | 2.10 | 33.3% |
| 2018 | USD 266M | 1.91 | 36.1% |
| 2017 | USD 247M | 1.76 | 32.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 21, 2005.
Who owns Quest Diagnostics Incorporated
- Insiders 0.43%
- Institutions 99.57%
- Public & others 0.00%
- Shares outstanding 110M
- Free float 109M
Top funds holding DGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.50M | 3.17% | -0.40% | Sep 2026 |
| Vanguard 500 Index Investor | 2.90M | 2.63% | -1.42% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 2.36M | 2.14% | -1.29% | Sep 2026 |
| iShares Core S&P 500 ETF | 1.47M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.43M | 1.30% | -0.18% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 1.35M | 1.23% | -0.25% | Oct 2026 |
| JHancock Disciplined Value Mid Cap I | 1.18M | 1.07% | -1.76% | Aug 2026 |
| EdgePoint Global Portfolio Series F | 1.18M | 1.07% | 0.00% | Jun 2026 |
| T. Rowe Price Dividend Growth | 1.10M | 0.99% | 0.00% | Sep 2026 |
| Vanguard MStar Value Index Investor | 1.05M | 0.95% | -0.55% | Sep 2026 |
| JHancock Disciplined Value I | 1.05M | 0.95% | -1.46% | Aug 2026 |
| Invesco S&P 500® Equal Weight ETF | 838K | 0.76% | +0.17% | Oct 2026 |
| JPMorgan Equity Income I | 826K | 0.75% | -26.39% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 807K | 0.73% | +0.87% | Oct 2026 |
| T. Rowe Price US Large-Cap Core | 746K | 0.68% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Value ETF | 689K | 0.62% | -3.84% | Sep 2026 |
| Victory Sycamore Established Value R | 660K | 0.60% | -37.44% | Sep 2026 |
| JPMorgan Mid Cap Value L | 626K | 0.57% | -4.38% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 624K | 0.57% | -0.34% | Sep 2026 |
| Fidelity Puritan | 599K | 0.54% | +110.50% | Jul 2026 |
Top institutions holding DGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.28M | 8.40% | +1.12% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.23M | 6.55% | +1.23% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.13M | 5.55% | +0.82% | Jun 2026 |
| State Street Corp | 5.52M | 5.00% | +2.52% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 5.44M | 4.93% | -13.54% | Jun 2026 |
| Boston Partners Global Investors, Inc | 4.74M | 4.30% | +18.25% | Jun 2026 |
| JPMorgan Chase & Co | 3.52M | 3.19% | -8.48% | Jun 2026 |
| Geode Capital Management, LLC | 3.14M | 2.84% | +1.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.46M | 2.23% | -0.78% | Jun 2026 |
| EdgePoint Investment | 2.25M | 2.04% | +0.16% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.00M | 1.81% | +0.75% | Sep 2026 |
| Bank of America Corp | 1.94M | 1.75% | +10.40% | Jun 2026 |
| Grantham, Mayo, Van Otterloo & Co., LLC | 1.89M | 1.71% | +0.28% | Jun 2026 |
| Wells Fargo & Co | 1.75M | 1.59% | -0.66% | Jun 2026 |
| Davis Selected Advisers | 1.56M | 1.41% | -3.84% | Jun 2026 |
| Victory Capital Management Inc. | 1.55M | 1.40% | -16.02% | Jun 2026 |
| NORGES BANK | 1.41M | 1.27% | +6.35% | Jun 2026 |
| FMR Inc | 1.40M | 1.27% | +48.45% | Jun 2026 |
| Amvescap Plc. | 1.38M | 1.25% | -15.83% | Jun 2026 |
| Northern Trust Corp | 1.13M | 1.02% | +1.19% | Jun 2026 |
Quest Diagnostics Incorporated company profile
- Company name
- Quest Diagnostics Incorporated
- Ticker
- DGX.US
- Exchange
- USA Stocks
- Listed since
- Dec 17, 1996
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 60,000
- Fiscal year end
- December
- Address
- 500 Plaza Drive, Secaucus, NJ, United States, 07094
- Phone
- 973 520 2700
- Website
- questdiagnostics.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Quest Diagnostics Incorporated management
10- Mr. James E. DavisChairman, CEO & President · born 1963
- Mr. Sam A. SamadExecutive VP & CFO · born 1970
- Mr. Michael E. Prevoznik J.D.Senior VP & General Counsel · born 1962
- Ms. Catherine T. DohertyExecutive Vice President of Regional Businesses · born 1963
- Mr. Karthik Kuppusamy Ph.D.Senior Vice President of Clinical Solutions · born 1970
- Mr. Michael J. DeppeSenior VP, Corporate Controller & Chief Accounting Officer · born 1967
- Mr. Murali BalakumarSenior VP and Chief Information & Digital Officer
- Ms. Damini ChokshiVice President of Investor Relations
- Ms. Kristin Lee Wallace Esq.Senior VP & Chief Compliance Officer
- Mr. Garry ClarkSenior VP and Chief Marketing & Communications Officer